

SUPPLEMENTAL FINANCIAL INFORMATION

HISTORICAL GAAP P&L TREND - CONSOLIDATED (\$000's)

	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155
Cost of sales	38,685	52,379	38,215	42,780	172,059	41,126	42,979	47,990	55,205	187,300	53,184	56,443	59,203	63,437	232,267
Gross profit	70,425	64,541	80,047	95,190	310,203	97,351	102,594	102,729	121,588	424,262	115,996	129,101	137,300	149,491	531,888
Operating expenses:															
Research and development	13,260	14,571	20,000	22,284	70,115	18,012	19,105	20,357	23,244	80,718	17,032	18,276	18,679	22,281	76,268
Sales, general and administrative	91,262	87,287	91,411	104,120	374,080	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526
Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784
Amortization of acquired intangibles	2,883	3,705	3,873	3,823	14,284	3,854	3,836	3,848	4,720	16,258	3,653	3,803	3,731	3,873	15,060
Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-	-	-	-
Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7	-	-	378
Gain on Settlement	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses	110,772	114,400	118,406	140,020	483,598	140,692	137,901	136,432	145,406	560,431	160,287	142,186	153,233	158,310	614,016
Operating Loss	(40,347)	(49,859)	(38,359)	(44,830)	(173,395)	(43,341)	(35,307)	(33,703)	(23,818)	(136,169)	(44,291)	(13,085)	(15,933)	(8,819)	(82,128)
Other expense, net:															
Cash interest expense, net	(3,014)	(3,038)	(3,581)	(3,367)	(13,000)	(4,283)	(4,754)	(5,417)	(5,967)	(20,421)	(5,356)	(5,289)	(5,312)	(5,184)	(21,141)
Noncash interest expense, net	(860)	(854)	(878)	(1,049)	(3,641)	(1,058)	(1,061)	(1,155)	(1,184)	(4,458)	(2,485)	(7,020)	(7,566)	(7,710)	(24,781)
Loss on debt extinguishment	-	-	-	-	-	-	-	-	-	-	(17,576)	-	-	-	(17,576)
Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	17,400	(16,780)	-	-	620
Other (expense) income, net	706	2,324	47	44	3,121	118	156	623	(1,922)	(1,025)	337	993	307	(34)	1,603
Total other expense, net	(3,168)	(1,568)	(4,412)	(4,372)	(13,520)	(5,223)	(5,659)	(5,949)	(9,073)	(25,904)	(7,680)	(28,096)	(12,571)	(12,928)	(61,275)
Net loss before taxes	(43,515)	(51,427)	(42,771)	(49,202)	(186,915)	(48,564)	(40,966)	(39,652)	(32,891)	(162,073)	(51,971)	(41,181)	(28,504)	(21,747)	(143,403)
Income tax provision (benefit)	14	(50)	(117)	(124)	(277)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)
Net loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)
Net loss per share, GAAP	\$ (0.40)	\$ (0.43)	\$ (0.35)	\$ (0.37)	\$ (1.54)	\$ (0.34)	\$ (0.29)	\$ (0.28)	\$ (0.23)	\$ (1.13)	\$ (0.35)	\$ (0.27)	\$ (0.19)	\$ (0.14)	\$ (0.96)
Weighted average shares outstanding, basic and diluted	109,751	118,719	122,468	133,750	121,242	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP RECONCILIATION - CONSOLIDATED (\$'000's)

NON-GAAP GROSS PROFIT & GROSS MARGIN	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Gross Profit, GAAP	\$ 70,425	\$ 64,541	\$ 80,047	\$ 95,190	\$ 310,203	\$ 97,351	\$ 102,594	\$ 102,729	\$ 121,588	\$ 424,262	\$ 115,996	\$ 129,101	\$ 137,300	\$ 149,491	\$ 531,888
+ Amortization of acquired intangible assets	220	220	221	278	939	307	307	308	(814)	108	50	64	65	66	245
+ Stock-based compensation	6,006	16,226	2,369	481	25,082	483	554	1,439	2,485	4,961	3,043	553	414	519	4,529
+ Purchase accounting adjustments on acquisitions	195	-	-	198	393	-	197	-	-	197	-	-	-	-	-
Non-GAAP Gross Profit	\$ 76,846	\$ 80,987	\$ 82,637	\$ 96,147	\$ 336,617	\$ 98,141	\$ 103,652	\$ 104,476	\$ 123,259	\$ 429,528	\$ 119,089	\$ 129,718	\$ 137,779	\$ 150,076	\$ 536,662
Gross Margin, GAAP	64.5%	55.2%	67.7%	69.0%	64.3%	70.3%	70.5%	68.2%	68.8%	69.4%	68.6%	69.6%	69.9%	70.2%	69.6%
+ Amortization of acquired intangible assets	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	-0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
+ Stock-based compensation	5.5%	13.9%	2.0%	0.3%	5.2%	0.3%	0.4%	1.0%	1.4%	0.8%	1.8%	0.3%	0.2%	0.2%	0.6%
+ Purchase accounting adjustments on acquisitions	0.2%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non-GAAP Gross Margin	70.4%	69.3%	69.9%	69.7%	69.8%	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%	70.1%	70.5%	70.2%
NON-GAAP OPERATING EXPENSES	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Research & Development, GAAP	\$ 13,260	\$ 14,571	\$ 20,000	\$ 22,284	\$ 70,115	\$ 18,012	\$ 19,105	\$ 20,357	\$ 23,244	\$ 80,718	\$ 17,032	\$ 18,276	\$ 18,679	\$ 22,281	\$ 76,268
- Stock-based compensation in R&D	1,317	1,480	6,790	9,154	18,741	4,315	5,614	7,207	9,894	27,030	3,644	4,159	3,307	8,421	19,531
Non-GAAP R&D	11,943	13,091	13,210	13,130	51,374	13,697	13,491	13,150	13,350	53,688	13,388	14,117	15,372	13,860	56,737
Sales General & Administrative, GAAP	91,262	87,287	91,411	104,120	374,080	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526
- Stock-based compensation in SG&A	9,139	6,488	10,914	10,880	37,421	12,524	10,792	8,816	9,154	41,286	15,631	10,912	12,658	10,458	49,659
- Other non-recurring expenses	1,349	-	-	-	1,349	-	1,608	-	-	1,608	-	-	-	-	-
Non-GAAP SG&A	80,774	80,799	80,497	93,240	335,310	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867
Other Operating Expense, GAAP	6,250	12,542	6,995	13,616	39,403	8,953	6,065	6,875	7,621	29,514	16,688	5,403	10,251	7,330	39,222
- Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784
- Amortization of acquired intangibles assets	2,883	3,705	3,873	3,823	14,284	3,854	3,836	3,848	4,720	16,258	3,653	3,803	3,731	3,873	15,060
- Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-	-	-	-
- Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7	-	-	378
Non-GAAP Other Operating Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-GAAP Operating Expenses	\$ 92,717	\$ 93,890	\$ 93,707	\$ 106,370	\$ 386,684	\$ 114,900	\$ 113,822	\$ 113,534	\$ 118,737	\$ 460,993	\$ 124,324	\$ 121,712	\$ 127,017	\$ 132,101	\$ 505,604
Non-GAAP Operating Expenses as a % of Revenue															
Research & development	10.9%	11.2%	11.2%	9.5%	10.7%	9.9%	9.3%	8.7%	7.6%	8.8%	7.9%	7.6%	7.8%	6.5%	7.4%
Sales, general & administrative	74.0%	69.1%	68.1%	67.6%	69.5%	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%
Total Non-GAAP Operating Expenses as a % of Revenue	84.9%	80.3%	79.2%	77.1%	80.2%	83.0%	78.2%	75.3%	67.2%	75.4%	73.8%	65.6%	64.6%	62.0%	66.2%

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP RECONCILIATION - CONSOLIDATED (\$000's)

ADJUSTED EBITDA	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Net loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)
Cash interest expense, net	3,014	3,038	3,581	3,367	13,000	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141
Noncash interest expense, net	860	854	878	1,049	3,641	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781
Loss on debt extinguishment	-	-	-	-	-	-	-	-	-	-	17,576	-	-	-	17,576
Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	(17,400)	16,780	-	-	(620)
Other (expense) income, net	(706)	(2,324)	(47)	(44)	(3,121)	(118)	(156)	(623)	1,922	1,025	(337)	(993)	(307)	34	(1,603)
Income tax provision (benefit)	14	(50)	(117)	(124)	(277)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)
Depreciation expense	8,589	9,758	10,651	11,918	40,916	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350
Amortization expense	3,103	3,925	4,094	4,101	15,223	4,161	4,143	4,156	3,906	16,366	4,153	4,316	4,267	4,406	17,142
Total EBITDA	(28,655)	(36,176)	(23,614)	(28,811)	(117,256)	(25,456)	(15,429)	(13,056)	(3,810)	(57,751)	(24,384)	6,243	3,223	10,282	(4,636)
+ Stock-based compensation	16,462	24,194	20,073	20,515	81,244	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719
+ Purchase accounting adjustments on acquisitions	195	-	-	198	393	-	197	-	-	197	-	-	-	-	-
+ Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784
+ Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-	-	-	-
+ Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7	-	-	378
+ Other non-recurring expenses	1,349	-	-	-	1,349	-	1,608	-	-	1,608	-	-	-	-	-
Total Adjusted EBITDA	\$ (7,282)	\$ (3,145)	\$ (419)	\$ 1,695	\$ (9,151)	\$ (3,035)	\$ 5,565	\$ 7,433	\$ 20,624	\$ 30,587	\$ 10,519	\$ 23,467	\$ 26,122	\$ 33,137	\$ 93,245
<i>Adjusted EBITDA as a % of Revenue</i>	<i>-6.7%</i>	<i>-2.7%</i>	<i>-0.4%</i>	<i>1.2%</i>	<i>-1.9%</i>	<i>-2.2%</i>	<i>3.8%</i>	<i>4.9%</i>	<i>11.7%</i>	<i>5.0%</i>	<i>6.2%</i>	<i>12.6%</i>	<i>13.3%</i>	<i>15.6%</i>	<i>12.2%</i>
NON-GAAP EARNINGS (LOSS) PER SHARE	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Net Loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)
+ Stock-based compensation	16,462	24,194	20,073	20,515	81,244	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719
+ Amortization of acquired intangible assets	3,103	3,925	4,094	4,101	15,223	4,161	4,143	4,156	3,906	16,366	3,703	3,867	3,796	3,939	15,305
+ Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7	-	-	378
+ Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-	-	-	-
+ Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784
+ Loss on Debt extinguishment	-	-	-	-	-	-	-	-	-	-	17,576	-	-	-	17,576
+ Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	(17,400)	16,780	-	-	(620)
+ Noncash interest expense, net	860	854	878	1,049	3,641	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781
+ Foreign exchange impact	(209)	265	7	16	79	(119)	(44)	(624)	1,592	805	(311)	(308)	(29)	(60)	(708)
+ Long-term income tax rate adjustment	5,168	3,522	3,912	3,693	16,295	5,448	4,606	3,800	21	13,875	2,928	(848)	(1,563)	(3,283)	(2,766)
Non-GAAP net income (loss)	\$ (14,778)	\$ (9,780)	\$ (10,568)	\$ (9,911)	\$ (45,037)	\$ (15,526)	\$ (11,725)	\$ (10,640)	\$ (2,195)	\$ (40,086)	\$ (8,023)	\$ 2,591	\$ 4,091	\$ 9,432	\$ 8,091
Non-GAAP net income (loss) per share	\$ (0.13)	\$ (0.08)	\$ (0.09)	\$ (0.07)	\$ (0.37)	\$ (0.11)	\$ (0.08)	\$ (0.07)	\$ (0.02)	\$ (0.28)	\$ (0.05)	\$ 0.02	\$ 0.03	\$ 0.06	\$ 0.05
Weighted avg shares outstanding, basic and diluted	109,751	118,719	122,468	133,750	121,242	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064

SUPPLEMENTAL FINANCIAL INFORMATION



NON-GAAP P&L TREND - CONSOLIDATED (\$000's)

	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155
Non-GAAP cost of sales	32,264	35,933	35,625	41,823	145,645	40,336	41,921	46,243	53,534	182,034	50,091	55,826	58,724	62,852	227,493
Non-GAAP gross profit	\$ 76,846	\$ 80,987	\$ 82,637	\$ 96,147	\$ 336,617	\$ 98,141	\$ 103,652	\$ 104,476	\$ 123,259	\$ 429,528	\$ 119,089	\$ 129,718	\$ 137,779	\$ 150,076	\$ 536,662
<i>Non-GAAP Gross Margin</i>	70.4%	69.3%	69.9%	69.7%	69.8%	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%	70.1%	70.5%	70.2%
Non-GAAP Operating expenses:															
Non-GAAP research & development	11,943	13,091	13,210	13,130	51,374	13,697	13,491	13,150	13,350	53,688	13,388	14,117	15,372	13,860	56,737
Non-GAAP sales, general & administrative	80,774	80,799	80,497	93,240	335,310	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867
Total non-GAAP operating expenses	\$ 92,717	\$ 93,890	\$ 93,707	\$ 106,370	\$ 386,684	\$ 114,900	\$ 113,822	\$ 113,534	\$ 118,737	\$ 460,993	\$ 124,774	\$ 121,712	\$ 127,017	\$ 132,101	\$ 505,604
<i>Non-GAAP R&D as % of revenue</i>	10.9%	11.2%	11.2%	9.5%	10.7%	9.9%	9.3%	8.7%	7.6%	8.8%	7.9%	7.6%	7.8%	6.5%	7.4%
<i>Non-GAAP SG&A as % of revenue</i>	74.0%	69.1%	68.1%	67.6%	69.5%	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%
<i>Total Non-GAAP OPEX as % of revenue</i>	84.9%	80.3%	79.2%	77.1%	80.2%	83.0%	78.2%	75.3%	67.2%	75.4%	73.8%	65.6%	64.6%	62.0%	66.2%
Non-GAAP operating income (loss)	(15,871)	(12,903)	(11,070)	(10,223)	(50,067)	(16,759)	(10,170)	(9,058)	4,522	(31,465)	(5,685)	8,006	10,762	17,975	31,058
<i>Op income (loss) as % of revenue</i>	-14.5%	-11.0%	-9.4%	-7.4%	-10.4%	-12.1%	-7.0%	-6.0%	2.6%	-5.1%	-3.4%	4.3%	5.5%	8.4%	4.1%
Less: Other amortization expense	-	-	-	-	-	-	-	-	-	-	450	449	471	467	1,837
Less: Depreciation expense	8,589	9,758	10,651	11,918	40,916	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350
Adjusted EBITDA	\$ (7,282)	\$ (3,145)	\$ (419)	\$ 1,695	\$ (9,151)	\$ (3,035)	\$ 5,565	\$ 7,433	\$ 20,624	\$ 30,587	\$ 10,519	\$ 23,467	\$ 26,122	\$ 33,137	\$ 93,245
<i>Adj EBITDA as % of revenue</i>	-6.7%	-2.7%	-0.4%	1.2%	-1.9%	-2.2%	3.8%	4.9%	11.7%	5.0%	6.2%	12.6%	13.3%	15.6%	12.2%
<i>Adj EBITDA drop through %</i>	14.2%	22.9%	30.5%	22.8%	22.0%	14.5%	30.4%	24.2%	48.8%	30.7%	44.1%	44.8%	40.8%	34.6%	41.1%

SUPPLEMENTAL FINANCIAL INFORMATION


REVENUE SUPPLEMENT
INFORMED BY EOS

	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025
Revenues:															
Products and services - Surgical	94,040	102,306	103,823	122,594	422,763	122,617	130,028	135,343	156,468	544,456	152,084	168,217	176,676	189,769	686,746
Products and services - EOS	15,070	14,614	14,439	15,376	59,499	15,860	15,545	15,376	20,325	67,106	17,096	17,327	19,827	23,159	77,409
Total revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155
Constant currency adjustments:															
Products and services - Surgical	17	(6)	4	42	57	67	18	(13)	(72)	-	180	80	75	93	428
Products and services - EOS	363	15	(319)	(266)	(207)	(88)	42	27	(146)	(165)	405	(167)	(435)	(589)	(786)
Revenue from products and services	380	9	(315)	(224)	(150)	(21)	60	14	(218)	(165)	585	(87)	(360)	(496)	(358)
TOTAL ADJUSTMENTS	380	9	(315)	(224)	(150)	(21)	60	14	(218)	(165)	585	(87)	(360)	(496)	(358)
Revenues at constant currency:															
Products and services - Surgical	94,057	102,300	103,827	122,636	422,820	122,684	130,046	135,330	156,396	544,456	152,264	168,297	176,751	189,862	687,174
Products and services - EOS	15,433	14,629	14,120	15,110	59,292	15,772	15,586	15,403	20,179	66,940	17,501	17,160	19,392	22,570	76,623
Total Revenue at Constant Currency	\$ 109,490	\$ 116,929	\$ 117,947	\$ 137,746	\$ 482,112	\$ 138,456	\$ 145,632	\$ 150,733	\$ 176,575	\$ 611,396	\$ 169,765	\$ 185,457	\$ 196,143	\$ 212,432	\$ 763,797
YOY GROWTH %															
Products and services - Surgical	55.1%	41.4%	31.9%	34.2%	39.5%	30.4%	27.1%	30.4%	27.6%	28.8%	24.0%	29.4%	30.5%	21.3%	26.1%
Products and services - EOS	46.8%	23.8%	29.9%	5.2%	24.4%	5.2%	6.4%	6.5%	32.2%	12.8%	7.8%	11.5%	28.9%	13.9%	15.4%
Total revenue from products and services	53.8%	38.9%	31.6%	30.2%	37.4%	26.9%	24.5%	27.4%	28.1%	26.8%	22.2%	27.5%	30.4%	20.4%	25.0%
YOY growth % at constant currency:															
Products and services - Surgical	55.1%	41.4%	31.9%	34.3%	39.5%	30.4%	27.1%	30.3%	27.5%	28.7%	24.1%	29.4%	30.6%	21.4%	26.2%
Products and services - EOS	46.1%	17.7%	19.1%	-3.4%	17.5%	2.2%	6.5%	9.1%	33.5%	12.8%	11.0%	10.1%	25.9%	11.8%	14.5%
Total Revenue Growth % at Constant Currency	53.7%	37.9%	30.2%	28.8%	36.4%	26.5%	24.5%	27.8%	28.2%	26.8%	22.6%	27.3%	30.1%	20.3%	24.9%